Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27971692 | 0.88 | MAPT (0.60) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL1393989 | 0.85 | MAPT (0.67) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL1393988 | 0.85 | MAPT (0.67) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL4194105 | 0.84 | MAPT (0.65) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL25972049 | 0.82 | MAPT (0.53) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL611308 | 0.81 | MAPT (0.67) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL1648849 | 0.81 | MAPT (0.60) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL27651274 | 0.81 | MAPT (0.60) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL21245799 | 0.80 | MAPT (0.63) | MAPTPOLBSMN1; SMN2LMNARAB9A | |
| SCHEMBL21406475 | 0.80 | PANK3 (0.63) | MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | MAPT 4056/4885POLB 2685/4885SMN1; SMN2 2404/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | MAPT 4056/4885POLB 2685/4885SMN1; SMN2 2404/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | MAPT 4056/4885POLB 2685/4885SMN1; SMN2 2404/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | MAPT 3496/4885POLB 2378/4885SMN1; SMN2 2443/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | MAPT 3496/4885POLB 2378/4885SMN1; SMN2 2443/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | MAPT 4056/4885POLB 2685/4885SMN1; SMN2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.